Effects of SA13353, a transient receptor potential vanilloid 1 agonist, on leukocyte infiltration in lipopolysaccharide-induced acute lung injury and ovalbumin-induced allergic airway inflammation.

Abstract

We recently demonstrated that SA13353, a transient receptor potential vanilloid 1 (TRPV1) agonist, reduced the severity of the symptoms of kidney injury, arthritis, and encephalomyelitis in disease models. Here, we investigated the effects of orally administered SA13353 on leukocyte infiltration in lipopolysaccharide (LPS)-induced acute lung injury and ovalbumin-induced allergic airway inflammation. In LPS-induced lung injury, SA13353 attenuated neutrophil infiltration and the increase of TNF-alpha and CINC-1 levels. In allergic airway inflammation, SA13353 tended to inhibit leukocyte infiltration and attenuated the increase of IL-4 and IL-12p40. These results suggest that somatosensory TRPV1 may play an anti-inflammatory role in lung inflammation.

• Authors: Fumio Tsuji, Masaaki Murai, Kenji Oki, Hiroyuki Inoue, Minoru Sasano, Hiroyuki Tanaka, Naoki Inagaki, Hiroyuki Aono
• Journal: Journal of pharmacological sciences (J Pharmacol Sci) Vol. 112 Issue 4 Pg. 487-90 ( 2010) ISSN: 1347-8648 [Electronic] Japan
• PMID: 20351486 (Publication Type: Journal Article)

Chemical References

• 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
• Lipopolysaccharides
• Pyridines
• TRPV Cation Channels
• TRPV1 protein, mouse
• Urea
• Ovalbumin

Topics

• Animals
• Inflammation (chemically induced)
• Leukocytes (cytology)
• Lipopolysaccharides (toxicity)
• Lung (drug effects, pathology)
• Mice
• Ovalbumin (toxicity)
• Pyridines (pharmacology)
• TRPV Cation Channels (agonists)
• Trachea (drug effects, pathology)
• Urea (analogs & derivatives, pharmacology)